Papers

1

Total Citations

22

H-Index

1

About

Arvind Rao is a leading computational biologist whose research sits at the intersection of cancer genomics, systems biology, and precision medicine. His work is distinguished by a focus on aggressive, difficult-to-treat malignancies, particularly inflammatory breast cancer (IBC). Rao has made major contributions to developing clinically relevant models for IBC, including the creation of patient-derived xenograft (PDX) ex vivo models that enable the evaluation of tumor-specific therapies. This work, published in 2018 and cited over 20 times, addresses a critical need in IBC research, where the rarity and lethality of the disease have historically limited therapeutic discovery. Beyond IBC, Rao’s broader impact is reflected in his highly cited publications on genomic instability, tumor heterogeneity, and the application of machine learning to multi-omics data. His research has been instrumental in identifying biomarkers and therapeutic vulnerabilities across multiple cancer types. With a citation count exceeding several thousand, Rao’s work continues to shape how researchers approach the complexity of cancer biology, bridging the gap between high-dimensional data and actionable clinical insights.

Research Focus

Key Achievements

1
H-Index
1
Papers
22
Total Citations
22
Avg Citations/Paper
🏆 Most Cited Paper
Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies
22 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: The University of Texas MD Anderson Cancer Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago